Janumet 50/1000mg

Sitagliptin and Metformin are two oral medications commonly used in combination to treat type 2 diabetes mellitus. Sitagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, while Metformin is a biguanide antidiabetic drug. Sitagliptin works by increasing the levels of incretin hormones, which stimulate insulin secretion and inhibit glucagon release, leading to reduced blood glucose levels. Metformin, on the other hand, decreases hepatic glucose production, increases insulin sensitivity in peripheral tissues, and improves glucose uptake by muscles, thereby lowering blood sugar levels.

The combination of Sitagliptin and Metformin offers several benefits in the management of type 2 diabetes. By targeting multiple pathways involved in glucose metabolism, it provides enhanced glycemic control compared to either drug alone. Additionally, the dual mechanism of action helps preserve pancreatic beta-cell function and reduce the risk of hypoglycemia. Sitagliptin and Metformin combination therapy is often prescribed as an adjunct to diet and exercise when monotherapy with either drug fails to achieve adequate glycemic control. It is generally well-tolerated, with a low risk of hypoglycemia and minimal side effects when used appropriately.